Changes of clinical characteristics after 2-year follow-up
±
By the end of 2-year follow-up, SR patients on average reduced 58.5% of baseline doses and stayed well under an average post-reduction dose CPZE 89.6 ± 79.7 mg/d, while statistically significant improvement was seen in symptom severity, clinical global impression, personal social functioning, and subjective quality of life. More SR patients were also able to have a full-time job. No such significant changes were seen in CR patients and FR patients (